公开(公告)号：IL297314A

公开(公告)日：2022-12-01

申请号：IL29731422

申请日：2022-10-13

Applicant: UNIV HEALTH NETWORK ,  BRAY MARK R ,  MASON JACQUELINE M ,  WEI XIN ,  DUNCAN GORDON

Inventor： BRAY MARK R ,  MASON JACQUELINE M ,  WEI XIN ,  DUNCAN GORDON

IPC: A61K31/4365 ,  A61K31/496 ,  A61P37/02

Abstract: Disclosed herein is a method of treating a subject with aberrant cytokine release from a disease or condition or at risk of developing aberrant cytokine release from a disease or condition. The method comprises administering to the subject an effective amount of a compound represented by structural formula (I): (I) or a pharmaceutically acceptable salt thereof. The variables in structural formula (I) are as described herein.

公开(公告)号：WO2012000103A8

公开(公告)日：2012-01-05

申请号：PCT/CA2011/000776

申请日：2011-07-04

Applicant: UNIVERSITY HEALTH NETWORK ,  PAN, Guohua ,  MASON, Jacqueline M. ,  WEI, Xin ,  FEHER, Miklos

Inventor： PAN, Guohua ,  MASON, Jacqueline M. ,  WEI, Xin ,  FEHER, Miklos

IPC: A61K31/496 ,  A61K31/415 ,  A61K31/4155 ,  A61K31/4439 ,  A61P35/00

Abstract: Provided herein are methods, uses and compositions for treating a patient with cancer wherein the cancer is characterized by a PTEN gene mutation. In particular embodiments, the methods comprise administering to the patient a composition comprising a therapeutically effective amount of a PLK4 antagonist, and identifying a patient that is likely to be responsive to PLK4 antagonist therapy, if PTEN gene mutation is present.

公开(公告)号：WO2012000103A1

公开(公告)日：2012-01-05

申请号：PCT/CA2011000776

申请日：2011-07-04

Applicant: UNIV HEALTH NETWORK ,  PAN GUOHUA ,  MASON JACQUELINE M ,  WEI XIN ,  FEHER MIKLOS

Inventor： PAN GUOHUA ,  MASON JACQUELINE M ,  WEI XIN ,  FEHER MIKLOS

IPC: A61K31/496 ,  A61K31/415 ,  A61K31/4155 ,  A61K31/4439 ,  A61P35/00

CPC classification number: A61K31/416 ,  A61K31/4439 ,  A61K31/495 ,  A61K31/496 ,  A61K31/497 ,  A61K31/5377

Abstract: Provided herein are methods, uses and compositions for treating a patient with cancer wherein the cancer is characterized by a PTEN gene mutation, hi particular embodiments, the methods comprise administering to the patient a composition comprising a therapeutically effective amount of a PLK4 antagonist, and identifying a patient that is likely to be responsive to PLK4 antagonist therapy, if PTEN gene mutation is present.

Abstract translation: 本文提供用于治疗癌症患者的方法，用途和组合物，其中癌症的特征在于PTEN基因突变。在具体实施方案中，所述方法包括向患者施用包含治疗有效量的PLK4拮抗剂的组合物，以及鉴定 如果存在PTEN基因突变，则可能对PLK4拮抗剂治疗有反应的患者。

公开(公告)号：WO2021108918A1

公开(公告)日：2021-06-10

申请号：PCT/CA2020/051668

申请日：2020-12-04

Applicant: UNIVERSITY HEALTH NETWORK ,  BRAY, Mark R. ,  MASON, Jacqueline M. ,  FLETCHER, Graham

Inventor： BRAY, Mark R. ,  MASON, Jacqueline M. ,  FLETCHER, Graham

IPC: A61K31/5377 ,  A61K31/194 ,  A61P35/02 ,  C07C57/15 ,  C07D413/14

Abstract: The invention is related to a method of treating a subject with acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, non-Hodgkin's lymphoma, Burkitt lymphoma, or diffuse large B-cell lymphoma, or myelodysplastic syndrome by administration of Compound (I): (I), or a pharmaceutically acceptable salt thereof.